Northwest Biotherapeutics, Inc. – OTC:NWBO
Northwest Biotherapeutics stock price today
$0.243
-0.03
-11.28%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Northwest Biotherapeutics stock price monthly change
-30.63%
month
Northwest Biotherapeutics stock price quarterly change
-30.63%
quarter
Northwest Biotherapeutics stock price yearly change
-61.94%
year
Northwest Biotherapeutics key metrics
Market Cap | 755.84M |
Enterprise value | 628.03M |
P/E | -5.99 |
EV/Sales | 373.16 |
EV/EBITDA | -6.44 |
Price/Sales | 361.70 |
Price/Book | -4.75 |
PEG ratio | 0.04 |
EPS | -0.06 |
Revenue | 1.33M |
EBITDA | -56.84M |
Income | -70.77M |
Revenue Q/Q | -67.72% |
Revenue Y/Y | -38.14% |
Profit margin | -6240.76% |
Oper. margin | -3991.74% |
Gross margin | 0% |
EBIT margin | -3991.74% |
EBITDA margin | -4254.64% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNorthwest Biotherapeutics stock price history
Northwest Biotherapeutics stock forecast
Northwest Biotherapeutics financial statements
| Jun 2023 | 201K | -14.44M | -7188.06% |
|---|---|---|---|
| Sep 2023 | 406K | -19.09M | -4704.19% |
| Dec 2023 | 445K | -18.91M | -4251.46% |
| Mar 2024 | 284K | -18.31M | -6447.89% |
| 2023-02-28 | -0.03 | -0.03 |
|---|
| Jun 2023 | 28438000 | 89.47M | 314.62% |
|---|---|---|---|
| Sep 2023 | 31492000 | 96.61M | 306.78% |
| Dec 2023 | 27944000 | 74.92M | 268.11% |
| Mar 2024 | 28646000 | 82.03M | 286.39% |
| Jun 2023 | -11.52M | -1.24M | 8.63M |
|---|---|---|---|
| Sep 2023 | -13.91M | -437K | 17.12M |
| Dec 2023 | -16.95M | -418K | 14.41M |
| Mar 2024 | -12.40M | -239K | 12.08M |
Northwest Biotherapeutics alternative data
| Aug 2023 | 22 |
|---|---|
| Sep 2023 | 22 |
| Oct 2023 | 22 |
| Nov 2023 | 22 |
| Dec 2023 | 22 |
| Jan 2024 | 22 |
| Feb 2024 | 22 |
| Mar 2024 | 25 |
| Apr 2024 | 25 |
| May 2024 | 25 |
| Jun 2024 | 25 |
| Jul 2024 | 25 |
Northwest Biotherapeutics other data
48.61%
-51.39%
of NWBO is owned by hedge funds
493.78K
-2.31M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 0 | 570000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | MALIK NAVID director | Common Stock | 150,000 | $0.82 | $123,450 | ||
Sale | MALIK NAVID director | Common Stock | 295,000 | $0.82 | $241,605 | ||
Sale | MALIK NAVID director | Common Stock | 125,000 | $0.84 | $104,375 | ||
Sale | POWERS LINDA F director, 10 perc.. | Restricted Common Stock, par value $0.001 | 804,146 | $0.17 | $136,705 | ||
Sale | POWERS LINDA F director, 10 perc.. | Restricted Common Stock, par value $0.001 | 3,558,639 | $0.17 | $604,969 | ||
Sale | POWERS LINDA F director, 10 perc.. | Class D-2 Warrants | 1,779,320 | N/A | N/A | ||
Option | BOSCH MARNIX L officer: Chief Technical Officer | Employee Stock Option (Right to Buy) | 7,940,182 | $0.25 | $1,985,046 | ||
Sale | COGNATE BIOSERVICES, INC. 10 percent owner | Common Stock, par value $0.001 | 1,118,092 | $4.22 | $4,718,348 | ||
Sale | COGNATE BIOSERVICES, INC. 10 percent owner | Common Stock, par value $0.001 | 650,000 | $4 | $2,600,000 | ||
Sale | COGNATE BIOSERVICES, INC. 10 percent owner | Common Stock | 149,502 | $5.02 | $750,500 |
| Insider | Compensation |
|---|---|
| Ms. Linda F. Powers J.D. (1956) Chairperson, Chief Executive Officer, Pres, Chief Financial Officer & Chief Accounting Officer | $700,000 |
| Mr. Leslie J. Goldman (1945) Senior Vice President & Gen. Counsel | $525,000 |
Dr. Marnix L. Bosch M.B.A., Ph.D., MBA (1959) Chief Technical Officer | $480,000 |
Northwest Bio: Is There Ever Going To Be A Right Time?
Northwest Biotherapeutics: Data Is Done, Just Wait For Approval
Northwest Biotherapeutics: Another Quarter Of Silence
Anavex: Increasing Shareholder Value Against All Odds
Northwest Bio: Buy Again, Wait For Regulatory Process
Northwest Bio: What A Comparison Analysis Says About Its Progress
-
What's the price of Northwest Biotherapeutics stock today?
One share of Northwest Biotherapeutics stock can currently be purchased for approximately $0.24.
-
When is Northwest Biotherapeutics's next earnings date?
Unfortunately, Northwest Biotherapeutics's (NWBO) next earnings date is currently unknown.
-
Does Northwest Biotherapeutics pay dividends?
No, Northwest Biotherapeutics does not pay dividends.
-
How much money does Northwest Biotherapeutics make?
Northwest Biotherapeutics has a market capitalization of 755.84M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 14.8% to 1.93M US dollars. Northwest Biotherapeutics made a loss 62.6M US dollars in net income (profit) last year or -$0.03 on an earnings per share basis.
-
What is Northwest Biotherapeutics's stock symbol?
Northwest Biotherapeutics, Inc. is traded on the OTC under the ticker symbol "NWBO".
-
What is Northwest Biotherapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Northwest Biotherapeutics?
Shares of Northwest Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Northwest Biotherapeutics's key executives?
Northwest Biotherapeutics's management team includes the following people:
- Ms. Linda F. Powers J.D. Chairperson, Chief Executive Officer, Pres, Chief Financial Officer & Chief Accounting Officer(age: 69, pay: $700,000)
- Mr. Leslie J. Goldman Senior Vice President & Gen. Counsel(age: 80, pay: $525,000)
- Dr. Marnix L. Bosch M.B.A., Ph.D., MBA Chief Technical Officer(age: 66, pay: $480,000)
-
How many employees does Northwest Biotherapeutics have?
As Jul 2024, Northwest Biotherapeutics employs 25 workers.
-
When Northwest Biotherapeutics went public?
Northwest Biotherapeutics, Inc. is publicly traded company for more then 23 years since IPO on 14 Dec 2001.
-
What is Northwest Biotherapeutics's official website?
The official website for Northwest Biotherapeutics is nwbio.com.
-
Where are Northwest Biotherapeutics's headquarters?
Northwest Biotherapeutics is headquartered at 4800 Montgomery Lane, Bethesda, MD.
-
How can i contact Northwest Biotherapeutics?
Northwest Biotherapeutics's mailing address is 4800 Montgomery Lane, Bethesda, MD and company can be reached via phone at +240 4979024.
Northwest Biotherapeutics company profile:
Northwest Biotherapeutics, Inc.
nwbio.comExchange:
OTC
Full time employees:
19
Industry:
Biotechnology
Sector:
Healthcare
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
4800 Montgomery Lane
Bethesda, MD 20814
Bethesda, MD 20814
CIK: 0001072379
ISIN: US66737P6007
:
